Larimar Therapeutics (LRMR) Net Cash Flow (2013 - 2025)

Larimar Therapeutics (LRMR) has reported Net Cash Flow for 13 consecutive years, with -$539000.0 the latest figure, recorded in Q2 2025.

• For the quarter ending Q2 2025, Net Cash Flow rose 99.31% year-over-year to -$539000.0; the trailing twelve-month figure through Jun 2025 stood at -$12.5 million (up 79.87% YoY), and the FY2025 full-year result was $52.2 million, up 816.33% from the prior year.
• Net Cash Flow climbed to -$539000.0 in Q2 2025 per LRMR's latest filing, from -$12.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $84.7 million in Q1 2023 and bottomed at -$77.8 million in Q2 2024.
• Historically, Net Cash Flow has averaged -$6.0 million across 5 years, with a median of -$7.5 million in 2022.
• The sharpest annual moves came in 2021 and 2023: Net Cash Flow tumbled 4781.15% in 2021, then surged 1224.37% in 2023.
• Over 5 years, Net Cash Flow stood at -$1.4 million in 2021, then slumped by 4047.2% to -$59.2 million in 2022, then surged by 79.72% to -$12.0 million in 2023, then jumped by 78.17% to -$2.6 million in 2024, then surged by 79.44% to -$539000.0 in 2025.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$539000.0, -$12.1 million, and -$2.6 million for Q2 2025, Q1 2025, and Q4 2024 respectively.